Specific ACE1/ACE2 genetic polymorphisms (20 SNPs) are significantly associated with increased severity of COVID-19 in hypertensive patients, with p-values <0.05 including rs2285666 (P=0.02) and p.Arg514Gly (P=0.01).
Meta-Analysis (n=7,149)
Yes
Do ACE1/ACE2 SNPs increase the severity of COVID-19 in hypertensive patients?
Specific ACE1 and ACE2 genetic polymorphisms are significantly associated with increased COVID-19 severity in hypertensive patients, suggesting a genetic basis for risk stratification.
p-value: p=<0.05 for 20 SNPs including rs2285666 (P=0.02), p.Arg514Gly (P=0.01), rs4240157 (P=0.01), rs4830965 (P=0.02), rs2074192 (P<0.01), rs4646142 (P=0.04), rs769062069 (P=0.01), rs6629110 (P=0.03), rs4646116 (P<0.01), rs1434130600 (P=0.01), rs867318181 (P=0.01), rs2106806 (P=0.01), rs1548474 (P=0.02), rs1476524 (P=0.03)
Background: ACE2 has been identified as the entry receptor for coronaviruses into human cells, including SARS-COV-2 that causes COVID-19. Since hypertension is a leading comorbidity in non-survivors of COVID-19, we aimed to identify relevant SNPs of ACE1, ACE2 that may associated with increased risk for SARS-CoV-2/SARS-CoV infection and there susceptibility to increase the cardiovascular diseases in hypertensive patients. Methods: Literature was searched in PubMed, Science direct and Google Scholar to identify studies that had either assessed the SNPs of ACE2 gene with SARS-CoV-2/SARS-CoV infection or suggested the SNPs that could possibly regulate ACE2 expression in different human tissues. Then make a list of these SNPs of ACE1 and ACE2 considering as potential candidate for investigating the genetic effects in future studies. Results: In 11 studies analyzed and interpreted, we identified and analyzed 37 mutations that affect ACE1/ACE2 causing an imbalance of the renin agiotensin aldosterone system and modifying the severity of Covid-19 in patients with hypertension. From the studies done so far, we found that there are 20 mutations among the 37 identified that affect the receptors of the renin angiotensin aldosterone system that are directly related to the severity of Covid-19 since they all present P values<0.05. Conclusion: This is the first meta-analysis that gathers all the polymorphisms that affect the receptors of the renin angiotensin aldosterone system, causing an imbalance in the latter and also increasing the expression of this receptor as the main receptor of Covid-19 severity.
PhD. Elkhazraji Abdelhak*1, MS. Nassih Safia2, Dr. Jeroundi Zineb1, Dr. Essahli Khadija1, Dr. El Orchi Ilham1, Pr Zahid Hafid1 (Sun,) conducted a meta-analysis in Hypertensive patients with COVID-19 infection, median age 50-70 years, majority male (56-63%), with common comorbidities including diabetes, cardiovascular disease, and obesity (n=7,149). ACE1/ACE2 SNPs (e.g., rs2285666, p.Arg514Gly, rs4240157, rs4830965, rs2074192, rs4646142, rs769062069) vs. Absence of SNPs or different alleles was evaluated on Association of ACE1/ACE2 SNPs with severity of COVID-19 in hypertensive patients (p=<0.05 for 20 SNPs including rs2285666 (P=0.02), p.Arg514Gly (P=0.01), rs4240157 (P=0.01), rs4830965 (P=0.02), rs2074192 (P<0.01), rs4646142 (P=0.04), rs769062069 (P=0.01), rs6629110 (P=0.03), rs4646116 (P<0.01), rs1434130600 (P=0.01), rs867318181 (P=0.01), rs2106806 (P=0.01), rs1548474 (P=0.02), rs1476524 (P=0.03)). Specific ACE1/ACE2 genetic polymorphisms (20 SNPs) are significantly associated with increased severity of COVID-19 in hypertensive patients, with p-values <0.05 including rs2285666 (P=0.02) and p.Arg514Gly (P=0.01).